Anus Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANS011 MIFTS: 46	Anus Cancer Categories: Rare diseases, Gastrointestinal diseases, Cancer diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Anus Cancer

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer ¹² ¹⁵

Anal Cancer ¹² ⁵³ ⁴³

Anus Neoplasms ⁴⁴ ⁷³

Anus Neoplasm ¹² ¹⁵

Malignant Neoplasm of Anus ⁷³

Malignant Anal Tumor ¹²

Cancer of the Anus ⁵³

Neoplasm of Anus ¹²

Anal Carcinoma ⁷³

Anal Neoplasm ¹²

Anal Tumors ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of anus and anal canal

Malignant neoplasm: Anal canal

Malignant neoplasm: Anus, unspecified

External Ids:

Disease Ontology ¹² DOID:14110 DOID:4551

ICD10 ³³ C21.0 C21.1

ICD9CM ³⁵ 154.2 154.3

NCIt ⁵⁰ C7379 C2877

SNOMED-CT ⁶⁸ 187762000 187764004 363352004 more

MeSH ⁴⁴ D001005

UMLS ⁷³ C0153445 C0153446 C0003463 more

Sources

Summaries for Anus Cancer

NIH Rare Diseases : ⁵³ Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Signs and symptoms of the condition include rectal bleeding; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of anal cancer is unknown. There appears to be a link between anal cancer and the human papillomavirus (HPV) infection. Other risk factors for anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system. The best treatment options for anal cancer depend on many factors including the stage of the condition, the location of the tumor and if there are associated conditions (i.e. HIV) but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Anus Cancer, also known as anal cancer, is related to anal canal squamous cell carcinoma and anal canal adenocarcinoma, and has symptoms including pruritus ani, abdominal pain and constipation. An important gene associated with Anus Cancer is SERPINB3 (Serpin Family B Member 3). The drugs Gardasil and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include the anus, testes and lymph node, and related phenotype is homeostasis/metabolism.

MedlinePlus : ⁴³ The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

Disease Ontology : ¹² A large intestine cancer that is located in the anus.

Wikipedia : ⁷⁶ Anal cancer is a cancer (malignant tumor) which arises from the anus, the distal opening of the... more...

Sources

Related Diseases for Anus Cancer

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)

#	Related Disease	Score	Top Affiliating Genes
1	anal canal squamous cell carcinoma	30.4	CDKN2A KRT5 SERPINB3
2	anal canal adenocarcinoma	30.0	CDX2 KRAS KRT7
3	anus sarcoma	10.9
4	hemorrhoid	10.9
5	vulva squamous cell carcinoma	10.8	CDKN2A SERPINB3
6	endocervical carcinoma	10.7	CDKN2A KRT7
7	vulval paget's disease	10.7	CDKN2A KRT7
8	adenoid basal cell carcinoma	10.7	CDKN2A KRT7
9	bladder carcinoma in situ	10.7	CDKN2A KRT7
10	glycogen-rich clear cell breast carcinoma	10.7	CDKN2A KRT7
11	well-differentiated liposarcoma	10.7	CDKN2A KRT7
12	ovary neuroendocrine neoplasm	10.7	CDX2 KRT7
13	vaginal benign neoplasm	10.6	CDX2 KRT7
14	appendix adenocarcinoma	10.6	CDX2 KRT7
15	vaginal adenoma	10.6	CDX2 KRT7
16	vaginal tubulovillous adenoma	10.6	CDX2 KRT7
17	mucinous adenofibroma	10.6	CDX2 KRT7
18	anus adenocarcinoma	10.6	CDX2 KRT7
19	glandular cystitis	10.6	CDX2 KRT7
20	keratinizing squamous cell carcinoma	10.6	CDKN2A KRT5
21	optic nerve sheath meningioma	10.6	CDKN2A KRT5
22	epithelial predominant wilms' tumor	10.6	CDX2 KRT7
23	balloon cell malignant melanoma	10.6	KRT5 KRT7
24	benign breast adenomyoepithelioma	10.6	KRT5 KRT7
25	ovarian mucinous adenocarcinoma	10.6	CDX2 KRT7
26	thymus adenocarcinoma	10.6	CDX2 KRT7
27	gastric diffuse adenocarcinoma	10.6	CDX2 KRT7
28	sensory organ benign neoplasm	10.6	KRT5 KRT7
29	bile duct mucoepidermoid carcinoma	10.6	KRT5 KRT7
30	bladder adenocarcinoma	10.6	CDX2 KRT7
31	middle ear adenoma	10.6	KRT5 KRT7
32	chronic cystitis	10.6	CDX2 KRT7
33	basaloid squamous cell carcinoma	10.6	CDKN2A KRT7
34	large cell acanthoma	10.6	KRT5 KRT7
35	mucinous ovarian cystadenoma	10.6	CDX2 KRT7
36	papillary adenoma	10.6	KRT5 KRT7
37	apocrine sweat gland neoplasm	10.5	KRT5 KRT7
38	schneiderian carcinoma	10.5	CDKN2A KRT5
39	apocrine adenocarcinoma	10.5	KRT5 KRT7
40	ampulla of vater adenocarcinoma	10.5	CDX2 KRT7
41	cervical clear cell adenocarcinoma	10.5	CDKN2A KRT5
42	inverted papilloma	10.5	CDKN2A KRT7 SERPINB3
43	vulva cancer	10.5	CDKN2A KRT7 SERPINB3
44	malignant biphasic mesothelioma	10.5	KRT5 KRT7
45	breast adenomyoepithelioma	10.5	KRT5 KRT7
46	breast myoepithelial neoplasm	10.5	KRT5 KRT7
47	ovarian mucinous neoplasm	10.5	CDX2 KRT7
48	cystic teratoma	10.5	CDX2 KRT7
49	atypical choroid plexus papilloma	10.4	KRT5 KRT7
50	horner's syndrome	10.4	CD6 KRT7

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Rectal Neoplasm

Graphical network of the top 20 diseases related to Anus Cancer:

Sources

Symptoms & Phenotypes for Anus Cancer

UMLS symptoms related to Anus Cancer:

pruritus ani, abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Anus Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	9.28	CARTPT CD6 CDKN2A CDX2 KRAS KRT7

Sources

Drugs & Therapeutics for Anus Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 1

61825-94-3

5310940 9887054 43805 6857599

Vaccines

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 4,Not Applicable

Antibodies

Phase 4,Phase 2,Phase 1,Not Applicable

Immunoglobulins

Phase 4,Phase 2,Phase 1,Not Applicable

Cola

Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

interferons

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Anesthetics

Phase 3,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Analgesics

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Central Nervous System Depressants

Phase 3,Phase 2

Adjuvants, Anesthesia

Phase 3

Adjuvants, Immunologic

Phase 3,Phase 1

Mitomycins

Phase 3,Phase 2,Phase 1,Early Phase 1

Gastrointestinal Agents

Phase 3

Narcotics

Phase 3

Analgesics, Opioid

Phase 3

Anesthetics, General

Phase 3

Anesthetics, Intravenous

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1,Early Phase 1

Peripheral Nervous System Agents

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 3

Interferon Inducers

Phase 3

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Indinavir

Approved

Phase 2

150378-17-9

5362440

Cetuximab

Approved

Phase 2,Phase 1

205923-56-4

56842117 2333

Vidarabine

Approved, Investigational

Phase 1, Phase 2,Phase 2

24356-66-9

32326 21704

Fludarabine

Approved

Phase 1, Phase 2,Phase 2

21679-14-1, 75607-67-9

30751

Menthol

Approved

Phase 2,Not Applicable

2216-51-5

16666

Formaldehyde

Approved, Vet_approved

Phase 2

50-00-0

712

Cidofovir

Approved

Phase 2

113852-37-2

60613

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2,Phase 2

50-18-0, 6055-19-2

2907

Interventional clinical trials:

(show top 50) (show all 185)

#	Name	Status	NCT ID	Phase	Drugs
1	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
2	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	Recruiting	NCT01824537	Phase 4
3	Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines	Recruiting	NCT03180034	Phase 4
4	Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients	Active, not recruiting	NCT02624349	Phase 4	Quadravalent human papillomavirus vaccine
5	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Unknown status	NCT00003652	Phase 3	cisplatin;fluorouracil
6	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
7	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
8	Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia	Completed	NCT01164722	Phase 3
9	An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)	Completed	NCT00090285	Phase 3
10	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)	Completed	NCT01651949	Phase 3
11	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer	Completed	NCT00075868	Phase 3	octreotide acetate
12	Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women	Completed	NCT01461096	Phase 3
13	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions	Recruiting	NCT02135419	Phase 3	imiquimod;fluorouracil
15	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy	Recruiting	NCT02369939	Phase 3	Mitomycin C;5-Fluorouracil
16	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	Recruiting	NCT02997553	Phase 3	Indocyanine green;Technetium99
17	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients	Enrolling by invitation	NCT02526953	Phase 3	Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
18	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer	Terminated	NCT00068744	Phase 2, Phase 3	cisplatin;fluorouracil;mitomycin C
19	Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer	Unknown status	NCT00955240	Phase 2	cisplatin;fluorouracil
20	International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel	Unknown status	NCT02051868	Phase 2	Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
21	A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy	Unknown status	NCT00754078	Phase 2
22	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
23	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
24	SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia	Completed	NCT00052897	Phase 1, Phase 2
25	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
26	Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00093379	Phase 2	Capecitabine;Oxaliplatin
27	Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus	Completed	NCT00550589	Phase 2	cidofovir
28	Vectibix for the Treatment of Anal Cancer	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
29	Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream	Completed	NCT00622440	Phase 2	AIJP (Arnebia Indigo Jade Pearl);Placebo
30	Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men	Completed	NCT00428285	Phase 2
31	Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males	Completed	NCT01209325	Phase 2
32	Erlotinib in Treating Patients With Advanced Kidney Cancer	Completed	NCT00045487	Phase 2	OSI-774
33	A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.	Completed	NCT01941966	Phase 2	Capecitabine;Mitomycins
34	T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers	Completed	NCT02280811	Phase 1, Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
35	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers	Completed	NCT01585428	Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
36	[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers	Completed	NCT01717391	Phase 2	fluorothymidine F 18
37	Oral Rigosertib for Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
38	Pembrolizumab in Refractory Metastatic Anal Cancer	Recruiting	NCT02919969	Phase 2	Pembrolizumab
39	Proton Therapy in Reducing Toxicity in Anal Cancer	Recruiting	NCT03018418	Phase 2	Chemotherapy
40	Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer	Recruiting	NCT02865135	Phase 1, Phase 2	DPX-E7 vaccine;Cyclophosphamide
41	Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer	Recruiting	NCT03381352	Phase 2	Capecitabine;Mitomycin C
42	A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma	Recruiting	NCT03519295	Phase 2	MPDL3280A;mDCF
43	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer	Recruiting	NCT03233711	Phase 2
44	VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Vir	Recruiting	NCT03499795	Phase 2
45	M7824 in Subjects With HPV Associated Malignancies	Recruiting	NCT03427411	Phase 2	M7824
46	Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life	Recruiting	NCT02701088	Phase 2	5Fluorouracile and Mitomycin-C
47	A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Recruiting	NCT03302858	Phase 2
48	Avelumab With Valproic Acid in Virus-associated Cancer	Recruiting	NCT03357757	Phase 2	Valproic Acid
49	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Recruiting	NCT02628067	Phase 2
50	A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	Recruiting	NCT02797964	Phase 1, Phase 2	SRA737

Search NIH Clinical Center for Anus Cancer

Cochrane evidence based reviews: anus neoplasms

Sources

Genetic Tests for Anus Cancer

Sources

Anatomical Context for Anus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Anus Cancer:

¹⁹

The Anus

MalaCards organs/tissues related to Anus Cancer:

⁴¹

Testes, Lymph Node, Skin, Lung, Liver, Breast, Kidney

Sources

Publications for Anus Cancer

Articles related to Anus Cancer:

(show all 20)

#	Title	Authors	Year
1	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. ( 27219019 )	Cacheux W....LiA"vre A.	2016
2	Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. ( 26457030 )	Belgioia L....CorvA^ R.	2015
3	EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. ( 24122611 )	Martin V....Frattini M.	2014
4	Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer. ( 25465729 )	Koerber S.A....Reuschenbach M.	2014
5	Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation? ( 23239699 )	Pettit L....Hartley A.	2013
6	Time trends in colon, rectum and anus cancer mortality between 1955 and 2008 in Japan, USA and Europe based on the WHO mortality database. ( 21875940 )	Saika K....Machii R.	2011
7	[Radiochemotherapy for locally advanced anal cancer]. ( 20431309 )	RAPdel C.	2010
8	Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. ( 19567510 )	Salit I.E....Mahony J.	2009
9	Comparison of time trends in colon, rectum and anus cancer incidence (1973-2002) in Asia, from 'Cancer Incidence in Five Continents, Vols IV-IX'. ( 19233893 )	Yako-Suketomo H....Marugame T.	2009
10	Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. ( 19777616 )	Contu S.S....Damin D.C.	2009
11	Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. ( 19923868 )	Lukan N....Hofheinz R.D.	2009
12	Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. ( 18501453 )	Widder J....PAPtter R.	2008
13	FHIT oncosuppressor gene expression profile in human anal cancers. ( 17393360 )	Zucchini C....Caramelli E.	2007
14	Prognostic significance of Cyclin A in epidermoid anal cancer. ( 16865241 )	Nilsson P.J....Glimelius B.	2006
15	The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer. ( 15868898 )	Mullerat J....Poulters L.W.	2005
16	Anal cancer: an HIV-associated cancer. ( 12852659 )	Klencke B.J....Palefsky J.M.	2003
17	Proliferation and p53 expression in anal cancer precursor lesions. ( 12926152 )	Mullerat J....Perrett C.W.	2003
18	Expression profile of epidermal differentiation complex genes in normal and anal cancer cells. ( 11713581 )	Zucchini C....Valvassori L.	2001
19	Expression analysis and mutational screening of the epithelium-specific ets gene-1 (ESE-1) in patients with squamous anal cancer. ( 10891534 )	Zucchini C....Valvassori L.	2000
20	Anorectal miscellany: pilonidal disease, anal cancer, Bowen's and Paget's diseases, foreign bodies, and hidradenitis suppurativa. ( 9922300 )	Billingham R.P.	1999

Sources

Genes for Anus Cancer

Genes related to Anus Cancer (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SERPINB3	Serpin Family B Member 3	Protein Coding	21.92	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	SLC14A2	Solute Carrier Family 14 Member 2	Protein Coding	21.39	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	21.1	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	RORC	RAR Related Orphan Receptor C	Protein Coding	18.66	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	KRT7	Keratin 7	Protein Coding	18.61	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	IARS	Isoleucyl-TRNA Synthetase	Protein Coding	18.44	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	CDX2	Caudal Type Homeobox 2	Protein Coding	18.14	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	KRT5	Keratin 5	Protein Coding	17.53	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	17.44	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	SMUG1	Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1	Protein Coding	15.85	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	CARTPT	CART Prepropeptide	Protein Coding	15.84	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	CD6	CD6 Molecule	Protein Coding	15.66	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Anus Cancer

Sources

Expression for Anus Cancer

Search GEO for disease gene expression data for Anus Cancer.

Sources

Pathways for Anus Cancer

Sources

GO Terms for Anus Cancer

Biological processes related to Anus Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cellular senescence	GO:2000774	8.62	CDKN2A KRAS

Sources

Sources for Anus Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia